Molinaro Caroline, Martoriati Alain, Pelinski Lydie, Cailliau Katia
Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France.
Univ. Lille, CNRS, Centrale Lille, Univ. Artois, UMR 8181-UCCS-Unité de Catalyse et Chimie du Solide, F-59000 Lille, France.
Cancers (Basel). 2020 Oct 5;12(10):2863. doi: 10.3390/cancers12102863.
Organometallics, such as copper compounds, are cancer chemotherapeutics used alone or in combination with other drugs. One small group of copper complexes exerts an effective inhibitory action on topoisomerases, which participate in the regulation of DNA topology. Copper complexes inhibitors of topoisomerases 1 and 2 work by different molecular mechanisms, analyzed herein. They allow genesis of DNA breaks after the formation of a ternary complex, or act in a catalytic mode, often display DNA intercalative properties and ROS production, and sometimes display dual effects. These amplified actions have repercussions on the cell cycle checkpoints and death effectors. Copper complexes of topoisomerase inhibitors are analyzed in a broader synthetic view and in the context of cancer cell mutations. Finally, new emerging treatment aspects are depicted to encourage the expansion of this family of highly active anticancer drugs and to expend their use in clinical trials and future cancer therapy.
有机金属化合物,如铜化合物,是单独使用或与其他药物联合使用的癌症化疗药物。一小类铜配合物对参与DNA拓扑结构调节的拓扑异构酶具有有效的抑制作用。本文分析了拓扑异构酶1和2的铜配合物抑制剂通过不同的分子机制发挥作用。它们在三元复合物形成后导致DNA断裂,或以催化模式起作用,通常表现出DNA嵌入特性和活性氧生成,有时还表现出双重作用。这些放大作用会对细胞周期检查点和死亡效应器产生影响。从更广泛的合成角度以及癌细胞突变的背景下分析了拓扑异构酶抑制剂的铜配合物。最后,描述了新出现的治疗方面,以鼓励扩大这一高活性抗癌药物家族,并扩大其在临床试验和未来癌症治疗中的应用。